Toleris

Startup

Toleris Biotherapeutics is a spin-off from the University of Würzburg, Germany that focuses on the development of targeted treatments for autoimmune diseases with significant unmet medical needs.

 Toleris founders discovered a novel mechanism that allows embryos to induce targeted immunological tolerance towards paternal antigen during pregnancy. AutoImmunity Modifying Biologicals (AIM Bios) are soluble proteins that use this mechanism to induce Treg-mediated dominant immunological tolerance in organs affected by autoimmune diseases. Toleris has prioritized therapeutic candidates for MOG antibody disease (MOGAD), multiple sclerosis and type 1 diabetes, has achieved a proof-of-concept in several animal models successfully has aligned the preclinical development until IND filing for the lead compound with the Paul Ehrlich Institute.

 The company’s business strategy involves out-licensing AIM Bios for selective indications, including MOGAD and type 1 diabetes, forming strategic partnerships with biotech companies and academic groups and partnering with venture capital to finance preclinical and clinical therapeutic projects.